Shares of CVRx, Inc. (NASDAQ: CVRX) are on a significant rise today following the approval of a key treatment therapy. As of the latest trading session, CVRX stock was valued at $10.53, marking an impressive increase of 11.01% on the US stock charts. This surge is attributed to a pivotal decision announced by CVRx, Inc. concerning a crucial therapeutic advancement for heart failure treatment.
CVRX Got New CPT Codes Endorsed
CVRx, Inc. revealed that the American Medical Association’s (AMA) CPT Editorial Panel has approved new Category I Current Procedural Terminology (CPT) codes for the Baroreflex Activation Therapy (Barostim). This therapy is specifically designed to address symptoms associated with heart failure. The approval of these codes was driven by growing utilization of Barostim therapy, supported by strong clinical evidence of its effectiveness.
The adoption of Category I CPT codes is expected to enhance reimbursement opportunities for healthcare providers performing the Barostim procedure. It will also improve access to this critical treatment for heart failure patients. This effort was championed by the Society for Vascular Surgery (SVS), with additional backing from the American College of Cardiology (ACC) and other medical organizations.
CPT Code Implementation and Interim Measures
The newly approved Category I CPT codes are scheduled for implementation on January 1, 2026. Until then, hospitals and physicians in the United States will continue utilizing the existing Category III codes for Barostim procedures. The AMA’s decision to reclassify Barostim to Category I underscores the therapy’s growing acceptance, proven safety, and clinical effectiveness in treating heart failure.
Positive Long-Term Data on Barostim Therapy
The long-term advantages of Barostim treatment are demonstrated by recent research, including that which was published in the “Journal of the American College of Cardiology: Heart Failure”. Over a 24-month period, data from the BeAT-HF study, which was published in 2024, showed that patients with heart failure saw notable increases in their quality of life.
Compared to patients getting GDMT alone, individuals receiving Barostim treatment in addition to GDMT reported significant improvements in their physical and mental health. The study focused on increased mobility, decreased tiredness symptoms, and an overall improvement in quality of life.
